论文部分内容阅读
目的探讨瑞格列奈在治疗2型糖尿病(T2DM)患者中的有效性及安全性。方法瑞格列奈1.0～4.0mg,每日3次口服。观察瑞格列奈口服12周后的有效性及安全性。结果患者治疗后与治疗前比较,空腹血糖(FBG)、餐后2小时血糖(P2hBG)、糖化血红蛋白(HbA1c)均有明显下降(P<0.05或P<0.01)。结论瑞格列奈降糖效果良好,安全性好,可有效降低T2DM患者HbA1c、FBG、P2hBG水平,提示瑞格列奈可作为T2DM治疗的常用药物。
Objective To investigate the efficacy and safety of repaglinide in the treatment of type 2 diabetes mellitus (T2DM). Methods Repaglinide 1.0 ~ 4.0mg, 3 times a day orally. Observe the effectiveness and safety of repaglinide for 12 weeks after oral administration. Results After treatment, FBG, P2hBG and HbA1c were significantly decreased (P <0.05 or P <0.01). Conclusion Repaglinide has good hypoglycemic effect and good safety. It can effectively reduce the levels of HbA1c, FBG and P2hBG in T2DM patients, suggesting that repaglinide can be used as a common drug for T2DM.